Program
Vaccines, Combined
Also written as “Hexavalent (DTwP-HepB-rPV-Hib) Vaccine”, “LBVD (Hexavalent vaccine)” and “DPT-IPV-Hib (Combined Vaccine)”.
Its studies are mostly in Hepatitis B · Diphtheria · Haemophilus Infections · Tetanus, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Tanabe Pharma | 20 open or running | phase 3since Jun 13, 2017 | Jun 13, 2017 | none ahead |
| LG Chem | 10 open or running | phase 3since Jul 11, 2022 | Jul 11, 2022 | none ahead |
| Serum Institute of India Pvt. | 11 open or running | phase 2since Sep 21, 2026 | Sep 21, 2026 | Oct 2027phase 2 · NCT07855172 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 13, 2017First study: phase 3 study in Haemophilus InfectionsNew to Tanabe PharmaTanabe Pharma · NCT03188692 · 33 enrolled · Japan
- Mar 24, 2019Phase 3 study in TetanusTanabe Pharma · NCT03891758 · 267 enrolled · Japan
- Jul 11, 2022LG Chem's first study: phase 3 study in DiphtheriaNew to LG ChemLG Chem · NCT05457946 · 60 enrolled · South Korea
- Sep 21, 2026Serum Institute of India Pvt.'s first study: phase 2 study in Diptheria ImmunizationNew to Serum Institute of India Pvt.Serum Institute of India Pvt. · NCT07855172 · 186 planned · Bangladesh
Ahead
- Oct 2027Primary completion: phase 2 study in Diptheria ImmunizationSerum Institute of India Pvt. · NCT07855172
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07855172Diptheria Immunization · Bangladesh | 2 | Recruiting | Serum Institute of India Pvt. | Oct 2027 | 186 |
| NCT05457946Diphtheria · South Korea | 3 | Completed | LG Chem | Feb 21, 2019 | 60 |
| NCT03891758Tetanus · Japan | 3 | Completed | Tanabe Pharma | Sep 18, 2019 | 267 |
| NCT03188692Haemophilus Infections · Japan | 3 | Completed | Tanabe Pharma | Nov 2, 2017 | 33 |
How it is read
Names in the registry
- “Hexavalent (DTwP-HepB-rPV-Hib) Vaccine”, 1 entry
- “LBVD (Hexavalent vaccine)”, 1 entry
- “DPT-IPV-Hib (Combined Vaccine)”, 1 entry
- “DPT-IPV-Hib”, 1 entry
Codes read as this program: BK1310.
Conditions, from the studies’ own filings
- Hepatitis B, 1 study
- Diphtheria, 1 study
- Haemophilus Infections, 1 study
- Tetanus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.